Cara Davis
Internal Medicine · Raleigh, NCNPI 1952338782
Payments from drug & device makers
Across 1,029 payments — averaging $17.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Novo Nordisk$2K
- AstraZeneca$2K
- Lilly USA, LLC$1K
- GSK$1K
- Boehringer Ingelheim$1K
- plus $8K from 54 others
What the payments were for
- Food & beverage$17,423100%
- Education$800%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$17,503 in reported general payments places this provider in the 95th percentile of 3,302 internal medicine providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tresiba Flextouch U-200Insulin Degludec | 12 | $24,411 |
| MounjaroTirzepatide | 19 | $19,382 |
| NeurontinGabapentin | 12 | $18,789 |
| EliquisApixaban | 17 | $14,518 |
| QuliptaAtogepant | 11 | $11,423 |
| JardianceEmpagliflozin | 14 | $10,610 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $8,878 |
| FarxigaDapagliflozin Propanediol | 11 | $5,894 |
| NexletolBempedoic Acid | 13 | $5,043 |
| SynthroidLevothyroxine Sodium | 28 | $2,075 |
| Gabapentin | 80 | $1,886 |
| Rosuvastatin Calcium | 179 | $1,668 |
| Estradiol | 35 | $1,406 |
| Nefazodone Hcl | 11 | $1,095 |
| Ipratropium Bromide | 51 | $1,071 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $1,336 | $19,38219 claims |
| PfizerEliquis | $757 | $14,51817 claims |
| AbbVieQulipta, Synthroid | $2,488 | $13,49839 claims |
| Boehringer IngelheimJardiance | $1,044 | $10,61014 claims |
| GSKTrelegy Ellipta | $1,074 | $8,87814 claims |
| AstraZenecaFarxiga | $1,611 | $5,89411 claims |
| Esperion Therapeutics, Inc.Nexletol | $506 | $5,04313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,302 internal medicine providers in North Carolina.
Other internal medicine in Raleigh
- John RubinoRaleigh$13M
- Wayne HarperRaleigh$6.7M
- Bhakti PaulRaleigh$536K
- Clifford CurtisRaleigh$376K
- Manesh PatelDurham$27.2M
- Saad UsmaniCharlotte$16.2M
- Christina KennellyCharlotte$15.4M
- Adam DevoreDurham$11.8M
- Krishnakumar UdayakumarDurham$11M
- Sylvia ShoffnerCary$7.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.